| Neuroprotective and symptomatic effects of cannabidiol in an animal model of Parkinson’s disease C Giuliano, M Francavilla, G Ongari, A Petese, C Ghezzi, N Rossini, ... International Journal of Molecular Sciences 22 (16), 8920, 2021 | 55 | 2021 |
| Profiling the biochemical signature of GBA‐related Parkinson's disease in peripheral blood mononuclear cells M Avenali, S Cerri, G Ongari, C Ghezzi, C Pacchetti, C Tassorelli, ... Movement Disorders 36 (5), 1267-1272, 2021 | 33 | 2021 |
| GBA mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with Parkinson’s disease S Cerri, C Ghezzi, G Ongari, S Croce, M Avenali, R Zangaglia, ... International journal of molecular sciences 22 (4), 2215, 2021 | 26 | 2021 |
| Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo … F Colucci, M Avenali, R De Micco, MF Poli, S Cerri, M Stanziano, A Bacila, ... BMJ Neurology Open 5 (2), 2023 | 7 | 2023 |
| Impaired Mitochondrial Respiration in REM‐Sleep Behavior Disorder: A Biomarker of Parkinson's Disease? G Ongari, C Ghezzi, D Di Martino, A Pisani, M Terzaghi, M Avenali, ... Movement Disorders 39 (2), 294-304, 2024 | 6 | 2024 |
| Phenotypic definition and genotype-phenotype correlates in PMPCA-related disease V Serpieri, T Biagini, C Mazzotta, R Pasquariello, A Rubegni, F Santorelli, ... Applied Sciences 11 (2), 748, 2021 | 4 | 2021 |
| Plasma neurofilament light chain level in isolated REM sleep behavior disorders, Parkinson’s disease and multiple system atrophy A Calculli, D Di Martino, G Ongari, S Gagliardi, P Grillo, E Capriglia, ... Parkinsonism & Related Disorders 122, 2024 | | 2024 |
| Combined Assessment of GCase Activity and α-synuclein as a Promising Blood Biomarker for GBA Mutation Carriers C Pasquini, M Avenali, SP Caminiti, S Cerri, M Gegg, M Toffoli, G Ongari, ... Parkinsonism & Related Disorders 122, 2024 | | 2024 |
| Functional Study of SNCA p.V15A Variant: Further Linking α‐Synuclein and Glucocerebrosidase M Avenali, S Cerri, I Palmieri, G Ongari, R Stiuso, G Buongarzone, ... Movement Disorders, 2024 | | 2024 |
| Evolution of biochemical and clinical signature of GBA-related Parkinson's Disease: a 2-year longitudinal study M Avenali, S Cerri, G Ongari, C Pacchetti, C Tassorelli, EM Valente, ... MOVEMENT DISORDERS 37, S561-S561, 2022 | | 2022 |
| Blood alpha-synuclein profile and lysosomal alterations distinguish GBA1-related Parkinson's disease from sporadic Parkinson's disease MA Avenali, SC Cerri, GO Ongari, CP Pacchetti, CT Tassorelli, ... MOVEMENT DISORDERS 35, S194-S194, 2020 | | 2020 |
| Distinctive blood alpha-synuclein profile and lysosomal alterations in Parkinson's Disease patients bearing GBA1 mutations M Avenali, S Cerri, G Ongari, C Pacchetti, C Tassorelli, EM Valente, ... EUROPEAN JOURNAL OF NEUROLOGY 27, 634-634, 2020 | | 2020 |
| Studio delle alterazioni lisosomiali associate al deficit di glucocerebrosidasi in linfociti di soggetti parkinsoniani portatori di mutazioni del gene GBA1 G ONGARI | | 2017 |
